Download MendeleyCPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma.
Ross, N.T., Lohmann, F., Carbonneau, S., Fazal, A., Weihofen, W.A., Gleim, S., Salcius, M., Sigoillot, F., Henault, M., Carl, S.H., Rodriguez-Molina, J.B., Miller, H.R., Brittain, S.M., Murphy, J., Zambrowski, M., Boynton, G., Wang, Y., Chen, A., Molind, G.J., Wilbertz, J.H., Artus-Revel, C.G., Jia, M., Akinjiyan, F.A., Turner, J., Knehr, J., Carbone, W., Schuierer, S., Reece-Hoyes, J.S., Xie, K., Saran, C., Williams, E.T., Roma, G., Spencer, M., Jenkins, J., George, E.L., Thomas, J.R., Michaud, G., Schirle, M., Tallarico, J., Passmore, L.A., Chao, J.A., Beckwith, R.E.J.(2020) Nat Chem Biol 16: 50-59
- PubMed: 31819276 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41589-019-0424-1
- Primary Citation Related Structures:
6M8Q - PubMed Abstract:
The post-genomic era has seen many advances in our understanding of cancer pathways, yet resistance and tumor heterogeneity necessitate multiple approaches to target even monogenic tumors. Here, we combine phenotypic screening with chemical genetics to identify pre-messenger RNA endonuclease cleavage and polyadenylation specificity factor 3 (CPSF3) as the target of JTE-607, a small molecule with previously unknown target. We show that CPSF3 represents a synthetic lethal node in a subset of acute myeloid leukemia (AML) and Ewing's sarcoma cancer cell lines. Inhibition of CPSF3 by JTE-607 alters expression of known downstream effectors in AML and Ewing's sarcoma lines, upregulates apoptosis and causes tumor-selective stasis in mouse xenografts. Mechanistically, it prevents the release of newly synthesized pre-mRNAs, resulting in read-through transcription and the formation of DNA-RNA hybrid R-loop structures. This study implicates pre-mRNA processing, and specifically CPSF3, as a druggable target providing an avenue to therapeutic intervention in cancer.
- Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Organizational Affiliation:
